Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00871637 · ClinicalTrials.gov registry record
Airway Macrophages and Sputum Milieu in Adult Subjects With Airflow Obstruction
A clinical trial, sponsored by University of Nebraska.
- Completed
- Registry status
- 30
- Enrollment target
NCT00871637: Completed study, sponsored by University of Nebraska.
NCT00871637 is a clinical trial that has completed, run by University of Nebraska. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00871637 has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Airway macrophage impairment is a central feature in the immunopathogenesis of chronic obstructive pulmonary disease, regardless of smoking status.
Primary Outcome
Determine if airway macrophages from adult participants with airflow obstruction demonstrate impaired innate immune cell surface marker expression and phagocytic ability compared to healthy controls.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-08-01 |
| Est. Completion | 2009-06-01 |
What the finished NCT00871637 record still lists
NCT00871637 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00871637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00871637 about?
NCT00871637 is a clinical study titled "Airway Macrophages and Sputum Milieu in Adult Subjects With Airflow Obstruction". Airway macrophage impairment is a central feature in the immunopathogenesis of chronic obstructive pulmonary disease, regardless of smoking status.
What is the current status of trial NCT00871637?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2008-08-01. Estimated completion is 2009-06-01.
Who is sponsoring clinical trial NCT00871637?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI